Short burst of radiation before Immuno-Chemo may boost esophageal cancer response
NCT ID NCT07678580
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests whether a short course of radiation followed by the immunotherapy drug tislelizumab plus chemotherapy can improve outcomes for people with a type of esophageal cancer that can be surgically removed. About 50 participants will receive either a low or high dose of radiation, then three cycles of tislelizumab and chemo, followed by surgery. The main goal is to see how many patients have no cancer cells left in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab, albumin-bound paclitaxel, carboplatin, and short-course radiotherapy
- What this could lead to
- If successful, this approach could increase the chance of eliminating all cancer before surgery, potentially improving long-term outcomes for people with esophageal cancer.
- What could go wrong
- This is an early Phase 2 study with only 50 participants, so results may not apply broadly. Side effects from the combination of radiation, immunotherapy, and chemotherapy could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tangdu Hospital, Fourth Military Medical University
Xi'an, Shaanxi, 710038, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI eye guide surgeons to safer, faster cancer removal?
- Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
- Can early tumor response guide smarter cancer treatment?
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
- Blood and tissue markers could forecast esophageal cancer return